The management of a public pharma company needed a high level opportunity assessment of all mitochondrial disorders.
MSC prepared and conducted a workshop to determine the MOAs, targets and organelle components of high client relevance. An opportunity assessment was done on companies, key opinion leaders, orphan drug designations, financial deals and clinical trials to identify potential partners as well as the client’s competitive landscape. A large-scale analysis – of reviews and published studies of patient case stories and clinical trials – revealed all molecules previously tested in various mitochondrial disorders together with their clinical results. The company management have subsequently implemented the content of the detailed dossier and executive summary presentation into its business plan and used the delivery in various discussions with partners and investors.